Recent News

• 06.11.2025 - TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
• 04.09.2025 - TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells
• 03.21.2025 - TCBP Announces Transition from Nasdaq to OTC Markets
• 03.18.2025 - TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
• 03.05.2025 - TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
• 02.20.2025 - TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
• 02.13.2025 - TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
• 02.10.2025 - TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
• 02.05.2025 - TCBP to Implement ADS Ratio Change
• 02.05.2025 - TCBP to Implement ADS Ratio Change

Recent Filings

• 05.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.09.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - NT 20-F Notification of inability to timely file Form 20-F
• 03.21.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.21.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.10.2025 - EX-99.1 EX-99.1